MED vs USNA vs NUS vs WW

For growth investors, USANA Health Sciences, Inc.

(USNA) is the stronger pick with 8. 3% revenue growth year-over-year, versus -36. 0% for Medifast, Inc. (MED). WW International, Inc. (WW) offers the better valuation at 0. 1x trailing P/E, making it the more compelling value choice. Analysts rate Medifast, Inc. (MED) a "Hold" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, WW International, Inc.

(WW) is the cheapest at 0. 1x versus USANA Health Sciences, Inc. at 33. 6x. On forward P/E, Nu Skin Enterprises, Inc. is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nu Skin Enterprises, Inc.

(NUS) delivered a total return of -80. 0%, compared to -99. 7% for WW International, Inc. (WW). Over 10 years, the gap is even starker: MED returned +23. 4% versus WW's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medifast, Inc.

(MED) is the lower-risk stock at 0. 94β versus Nu Skin Enterprises, Inc. 's 1. 49β — meaning NUS is approximately 58% more volatile than MED relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 147% for WW International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), USANA Health Sciences, Inc.

(USNA) is pulling ahead at 8. 3% versus -36. 0% for Medifast, Inc. (MED). On earnings-per-share growth, the picture is similar: WW International, Inc. grew EPS 25. 4% year-over-year, compared to -994. 7% for Medifast, Inc.. Over a 3-year CAGR, USNA leads at -2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

WW International, Inc.

(WW) is the more profitable company, earning 148. 6% net margin versus -4. 8% for Medifast, Inc. — meaning it keeps 148. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WW leads at 6. 5% versus -3. 7% for MED. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Nu Skin Enterprises, Inc.

(NUS) trades at 7. 0x forward P/E versus 11. 2x for USANA Health Sciences, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WW: 276. 2% to $34. 50.

In this comparison, NUS (3.

4% yield), MED (0. 1% yield) pay a dividend. USNA, WW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medifast, Inc.

(MED) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94)). Both have compounded well over 10 years (MED: +23. 4%, USNA: -68. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MED (Consumer Cyclical) and USNA (Consumer Defensive) and NUS (Consumer Defensive) and WW (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MED is a small-cap quality compounder stock; USNA is a small-cap quality compounder stock; NUS is a small-cap deep-value stock; WW is a small-cap deep-value stock. NUS pays a dividend while MED, USNA, WW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.